ATAI Life Sciences NV - Asset Resilience Ratio
ATAI Life Sciences NV (9VC) has an Asset Resilience Ratio of 35.11% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is ATAI Life Sciences NV's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how ATAI Life Sciences NV's Asset Resilience Ratio has changed over time. See ATAI Life Sciences NV balance sheet independence to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ATAI Life Sciences NV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ATAI Life Sciences NV (9VC) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €84.20 Million | 35.11% |
| Total Liquid Assets | €84.20 Million | 35.11% |
Asset Resilience Insights
- Very High Liquidity: ATAI Life Sciences NV maintains exceptional liquid asset reserves at 35.11% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ATAI Life Sciences NV Industry Peers by Asset Resilience Ratio
Compare ATAI Life Sciences NV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC |
Biotechnology | -55.36% |
|
Krystal Biotech Inc
NASDAQ:KRYS |
Biotechnology | 23.06% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
BB Biotech AG
SW:BION |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for ATAI Life Sciences NV (2021–2024)
The table below shows the annual Asset Resilience Ratio data for ATAI Life Sciences NV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 28.12% | €44.83 Million ≈ $52.41 Million |
€159.39 Million ≈ $186.34 Million |
-17.61pp |
| 2023-12-31 | 45.74% | €134.22 Million ≈ $156.92 Million |
€293.48 Million ≈ $343.11 Million |
+18.73pp |
| 2022-12-31 | 27.01% | €82.50 Million ≈ $96.45 Million |
€305.44 Million ≈ $357.09 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€414.17 Million ≈ $484.20 Million |
-- |
About ATAI Life Sciences NV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more